Release date: 2015-01-22
In the past year, we have seen exciting advances in personalized medicine, especially in the field of cancer. Genetic differentiation, biomarker identification and diagnosis, targeted therapy and prognosis testing are all striding forward. Looking forward to 2015, we found that on the one hand, the obstacles to cancer treatment will be higher; on the other hand, personalized medicine, cancer research and treatment are also facing huge opportunities.
In 2015, many “players†are preparing to become “game changers†in the field of cancer treatment, including big data, immunotherapy, combination therapies and biomarkers. According to the analysis of the GEN website, the following four major trends will be the direction of cancer drug development and personalized medical development.
1, big data: stop at the big
The demand for big data in clinical trials and treatment is growing. We see a number of organizations developing data devices to store genomic data, such as Genomic Data Commons at the University of Chicago. The use of big data has a huge impact on the development of cancer therapies. The more data that can be relied upon, the more reliable the personalized therapy tailored to the patient. However, what needs to be improved along with the quantity is the quality of the data collected and analyzed by researchers.
At present, the lack of standardization of data collection, sharing and analysis leads to problems in the accuracy of data. This is also the problem that researchers in the field are trying to solve. In order for big data to become more useful, the quality of the data must also increase. In 2014, the Journal of American Medical Association reported that in reanalysis, in many cases, clinical trial data could not match the raw data obtained from the original researchers.
2, combination drugs will become a trend
In 2015, the importance of combination therapy for the industry and patients will increase significantly. At present, combination therapy has attracted widespread attention in the industry because of its excellent results in clinical trials, especially for advanced breast cancer. However, in order for the combination therapy to develop faster, the current regulatory environment and drug review process needs to be tuned to support simultaneous detection of multiple drugs.
The FDA's classic review process is to test a single drug rather than simultaneously evaluating both drugs. In 2015, the field needs to address this issue so that combination therapy can fight more cancers such as melanoma, lung cancer and prostate cancer.
3, immunotherapy will be more eye-catching
In 2015, the immunization drug application war will be upgraded because pharmaceutical companies invest a lot of resources to develop related drugs and therapies. In addition, relative to advanced cancer, the development of immunotherapy for patients with early cancer will be more concerned. Although immunosurge is expected to increase in 2015, standardized clinical trial data will be an important driver of the development of immunotherapy.
In addition, researchers in the field are developing a standard method to effectively score patients' immunoprofiles and develop biomarkers that can predict treatment response. It is very challenging for scientists to evaluate the immune profile, so more image quantification techniques are needed to harness the full potential of immunotherapy.
4, biomarker research enthusiasm will continue to increase
Researchers' enthusiasm for biomarker research last year will continue to increase in 2015. Pharmaceutical companies recognize the importance of predictive biomarkers for first- and second-line therapeutic drug reviews. Doctors are looking for better tests to provide more targeted treatments for patients. However, the discovery of good biomarkers depends on many factors and is more challenging than we think.
In the coming year, personalized medicine faces enormous opportunities for development. However, in order to achieve milestone progress, the academic and medical communities need to overcome these four challenges together to promote the advancement of personalized medicine.
Source: biodiscover
Metallurgical Microscope
Metallurgical Microscope,Laboratory Microscope,Upright Metallurgical Microscope,Upright Laboratory Microscope
NINGBO VANCO INSTRUMENT CO.,LTD , https://www.vancoscope.com